---

Connecting with the Neuro-Oncology Community at AACR’s Brain Cancer Research Conference

CNSide Diagnostics is looking forward to attending the upcoming AACR Special Conference in Cancer Research: Brain Cancer in Philadelphia.

Hosted by the American Association for Cancer Research, the conference brings together leading clinicians, researchers, and innovators focused on advancing the understanding and treatment of brain cancers and central nervous system (CNS) malignancies.

The meeting will feature discussions on some of the most important and rapidly evolving areas in neuro-oncology, including:

• Glioma biology and therapeutics
• Neuro-immuno-oncology
• Cellular therapies
• CNS metastases
• Emerging translational research
• Advances in brain tumor diagnostics and treatment strategies

As the neuro-oncology landscape continues to evolve, conferences like AACR provide an important opportunity for collaboration, scientific exchange, and discussion around emerging technologies that may help improve patient care.

---

Advancing CSF-Based Diagnostics in Neuro-Oncology

At the conference, the CNSide Diagnostics team looks forward to engaging with researchers and clinicians about the evolving role of cerebrospinal fluid (CSF)-based diagnostics in neuro-oncology.

The CNSide® Cerebrospinal Fluid Assay Platform is designed to provide additional diagnostic insights for patients with suspected leptomeningeal metastases (LM), a serious and difficult-to-diagnose complication of advanced cancer.

Leptomeningeal metastases occur when cancer spreads to the membranes surrounding the brain and spinal cord. Diagnosing LM can be particularly challenging due to limitations associated with traditional diagnostic approaches, making innovation in this area increasingly important.

CNSide® is focused on supporting clinicians through advanced CSF analysis and tumor cell characterization technologies designed to enhance diagnostic evaluation in patients with suspected CNS involvement.

---

Meet the CNSide Diagnostics Team at AACR

If you are attending the AACR Special Conference in Cancer Research: Brain Cancer, we welcome the opportunity to connect and discuss the future of neuro-oncology diagnostics and the evolving role of CSF-based testing in patients with suspected leptomeningeal metastases.

Learn more about the conference here: AACR Brain Cancer Conference Information

---

Interested in meeting with the CNSide Diagnostics team during the event? Contact CNSide Diagnostics

---

About CNSide® Diagnostics

CNSide® is a proprietary diagnostic platform designed to detect and characterize tumor cells in cerebrospinal fluid (CSF) from patients with leptomeningeal metastases. The platform combines advanced technologies to support enhanced diagnostic insights and help address unmet needs in neuro-oncology.nsights and help address unmet needs in neuro-oncology.